Generic drugs are drugs with the chemical makeup of a drug equivalent to an existing branded drug. These drugs are cheaper and equivalent to branded drugs in dosage, strength, route of administration, quality, performance, and application. Generic drugs are subjected to government regulations in various countries rather than being associated with a particular company.

The major factors that contribute to the growth of the generic drugs market include increasing prevalence of chronic diseases, diabetes & cardiovascular diseases, growth in geriatric population, increasing healthcare expenditure, high demand for generic medicines, and large number of patent expired branded drugs. However, stringent governmental regulations and adverse effects associated with drugs are expected to restrain the market development. The rising demand for newer versions of generic drugs, additional numbers of clinical trials, and large numbers of licensing & partnering strategies to launch new products by key vendors contributes to significant demand for generic drugs in the near future.

The global generic drugs market is segmented on the basis of product type, application, distribution channel, and region. On the basis of product type, the market is segmented into simple generics, super generics, and biosimilars. Based on application the market is divided into cardiovascular products, anti-infective drugs, anti-arthritis drugs, central nervous system drugs, anti-cancer drugs, respiratory products, and others. On the basis of distribution channel, the market is segmented into hospitals, pharmacies, private clinics, drug stores, retail pharmacies, and others. Geographically, the market has been analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The key players that operate in this market include Abbott Laboratories, Teva Pharmaceutical Industries Ltd., ALLERGAN, Sandoz International GmbH, Mylan N.V., STADA Arzneimittel AG, Baxter International Inc., Eli Lilly and Company, GlaxoSmithKline Plc., and Pfizer Inc.

Key Benefits

• The study provides an in-depth analysis of the global generic drugs market with current trends and future estimations to elucidate imminent investment pockets.
• The report provides information about the current and upcoming trends in the global generic drugs market from 2016 to 2023, which helps determine prevailing opportunities.
• Comprehensive analysis of factors that drive and restrict the growth of the global generic drugs market has been provided.
• Identification of factors that are instrumental in changing the market scenario, rise in opportunities, and identification of key companies that can influence this market on a global and regional scale have been provided.
• Key market players within the market have been profiled in this report and their strategies are analyzed thoroughly, which help understand the competitive outlook of the global generic drugs market.

Generic Drugs Market Key Segments:

By Product Type

• Simple Generics

• Super Generics
• Biosimilars

By Application

• Cardiovascular Products
• Anti-Infective Drugs
• Anti-Arthritis Drugs
• Central Nervous System Drugs
• Anti-Cancer Drug
• Respiratory Products
• Others

By Distribution Channel

• Hospitals
• Pharmacies
• Private Clinics
• Drug Stores
• Retail Pharmacies
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • Rest of Asia-Pacific
• LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

CHAPTER 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

CHAPTER 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. MARKET SHARE ANALYSIS, 2016
3.4. PORTER’S FIVE FORCES ANALYSIS

3.4.1. MARKET DYNAMICS
3.4.2. Drivers
3.4.3. Restraints
3.4.4. Opportunities

CHAPTER 4 GENERIC DRUGS MARKET, BY PRODUCT TYPE

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. SIMPLE GENERICS

4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast

4.3. SUPER GENERICS

4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast

4.4. BIOSIMILARS 

4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast

CHAPTER 5 GENERIC DRUGS MARKET, BY APPLICATION

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. CARDIOVASCULAR DRUGS

5.2.1. Market size and forecast

5.3. ANTI-INFECTIVE DRUGS

5.3.1. Market size and forecast

5.4. ANTI-ARTHRITIS DRUGS

5.4.1. Market size and forecast

5.5. CENTRAL NERVOUS SYSTEM DRUGS

5.5.1. Market size and forecast

5.6. ANTI-CANCER DRUGS

5.6.1. Market size and forecast

5.7. RESPIRATORY DRUGS

5.7.1. Market size and forecast

5.8. OTHERS

5.8.1. Market size and forecast

CHAPTER 6 GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL 

6.1. OVERVIEW

6.1.1. Market size and forecast

6.2. HOSPITALS

6.2.1. Market size and forecast

6.3. PHARMACIES

6.3.1. Market size and forecast

6.4. PRIVATE CLINICS

6.4.1. Market size and forecast

6.5. DRUG STORES

6.5.1. Market size and forecast

6.6. RETAIL PHARMACIES

6.6.1. Market size and forecast

6.7. OTHERS

6.7.1. Market size and forecast

CHAPTER 7 GENERIC DRUGS MARKET, BY REGION

7.1. OVERVIEW
7.2. NORTH AMERICA

7.2.1. Key market trends
7.2.2. Key growth factors and opportunities
7.2.3. Market size and forecast

7.2.3.1. U.S. market size and forecast
7.2.3.2. Canada market size and forecast
7.2.3.3. Mexico market size and forecast

7.2.4. North America generic drugs market by product type
7.2.5. North America generic drugs market by application
7.2.6. North America generic drugs market by distribution channel

7.3. EUROPE

7.3.1. Key market trends
7.3.2. Key growth factors and opportunities
7.3.3. Market size and forecast

7.3.3.1. Germany market size and forecast
7.3.3.2. France market size and forecast
7.3.3.3. UK market size and forecast
7.3.3.4. Italy market size and forecast
7.3.3.5. Spain market size and forecast
7.3.3.6. Rest of Europe market size and forecast

7.3.4. Europe generic drugs market by product type
7.3.5. Europe generic drugs market by application
7.3.6. Europe generic drugs market by distribution channel

7.4. ASIA-PACIFIC

7.4.1. Key market trends
7.4.2. Key growth factors and opportunities
7.4.3. Market size and forecast

7.4.3.1. Japan market size and forecast
7.4.3.2. China market size and forecast
7.4.3.3. Australia market size and forecast
7.4.3.4. India market size and forecast
7.4.3.5. South Korea market size and forecast
7.4.3.6. Taiwan market size and forecast
7.4.3.7. Rest of Asia-Pacific market size and forecast

7.4.4. Asia-Pacific generic drugs market by product type
7.4.5. Asia-Pacific generic drugs market by application
7.4.6. Asia-Pacific generic drugs market by distribution channel

7.5. LAMEA

7.5.1. Key market trends
7.5.2. Key growth factors and opportunities
7.5.3. Market size and forecast

7.5.3.1. Brazil market size and forecast
7.5.3.2. Turkey market size and forecast
7.5.3.3. Saudi Arabia market size and forecast
7.5.3.4. South Africa market size and forecast
7.5.3.5. Rest of LAMEA market size and forecast

7.5.4. LAMEA generic drugs market by product type
7.5.5. LAMEA generic drugs market by application
7.5.6. LAMEA generic drugs market by distribution channel

CHAPTER 8 COMPANY PROFILES

8.1. ABBOTT LABORATORIES

8.1.1. Operating business segments
8.1.2. Business performance
8.1.3. Key strategic moves and developments

8.2. TEVA PHARMACEUTICAL INDUSTRIES LTD.

8.2.1. Operating business segments
8.2.2. Business performance
8.2.3. Key strategic moves and developments

8.3. ALLERGAN PLC

8.3.1. Operating business segments
8.3.2. Business performance
8.3.3. Key strategic moves and developments

8.4. SANDOZ INTERNATIONAL GMBH

8.4.1. Operating business segments
8.4.2. Business performance
8.4.3. Key strategic moves and developments

8.5. MYLAN N.V.

8.5.1. Operating business segments
8.5.2. Business performance
8.5.3. Key strategic moves and developments

8.6. STADA ARZNEIMITTEL AG

8.6.1. Operating business segments
8.6.2. Business performance
8.6.3. Key strategic moves and developments

8.7. BAXTER INTERNATIONAL INC.

8.7.1. Operating business segments
8.7.2. Business performance
8.7.3. Key strategic moves and developments

8.8. ELI LILLY AND COMPANY

8.8.1. Operating business segments
8.8.2. Business performance
8.8.3. Key strategic moves and developments

8.9. GLAXOSMITHKLINE PLC

8.9.1. Operating business segments
8.9.2. Business performance
8.9.3. Key strategic moves and developments

8.10. PFIZER INC.

8.10.1. Operating business segments
8.10.2. Business performance
8.10.3. Key strategic moves and developments